On July 30th, Gelonhui reported that Haitai Xinguang (688677.SH) said on the investor interaction platform that the sales of the 1788 system were good according to feedback from US customers. Due to the epidemic and the delayed listing of the 1788 system, the high inventory of endoscopes supporting the 1788 system caused customers to gradually consume inventory, resulting in a phased reduction in the company's delivery to customers. In addition, the company's subsidiary, American Omik, has been certified by US customers to produce and sell endoscope finished products in its US subsidiary. After mutual agreement, American customers placed orders with American Omik, and American Omik delivered the goods to American customers. The company and American customers are currently testing this business process, and it will be officially launched after passing the test. This business process is conducive to the company's avoidance of international environmental risks and ensures the safety of overseas business. In the second half of this year, the company will further accelerate the construction of Thailand's subsidiary's production capacity and promote related certifications, which can further reduce the potential impact of international policies such as tariffs on the company's business.